Eli Lilly's $65.2B 2025 Revenue — Half from GLP-1 Drugs — Fuels Pharma M&A Spree
Biopharma acquisitions surged in Q1 2026 with 14 deals over $500M. Eli Lilly earned $65.2 billion in 2025, roughly half from Mounjaro and Zepbound, fueling an industry-wide M&A wave.